Albany Molecular Resh Inc (NASDAQ:AMRI)

CAPS Rating: 2 out of 5

The Company is a global chemistry-based drug discovery and development company focused on identifying and developing novel biologically active small molecules with applications in the drug market.


Player Avatar zzlangerhans (99.85) Submitted: 8/29/2011 3:02:24 AM : Outperform Start Price: $3.49 AMRI Score: +158.62

How could anyone not be excited about a company called Albany Molecular Research? I mean it's Albany, come on! The Real World Albany? Real Housewives of Albany? No?

Fine then. We'll try and look at the company on its merits instead. When I see a stock carving out new all-time lows with no sign of a plateau I start looking for reasons why the company might be going out of business, and with AMR I'm just not finding them. The company has separate and solid revenue streams from Allegra royalties and outsourced contract research. Quarterly revenues and cash reserves have been stable for at least a year, dating back to when the share price was over 6. In the midst of the 2009 decline, the stock traded at 8. Meanwhile, debt remains low and manageable.

The company projects continuing stable revenues and expenses through the end of the year. Despite the instability in the economy and the markets, I have not noted a significant tendency of large or small pharmaceutical companies and biotechs to reduce their research budgets. AMR certainly seems more likely to survive the current decline than the one of early 2009, which they weathered well.

Featured Broker Partners